|Videos|November 28, 2022
Factors in Selecting First-Line Therapy for Patients With Advanced RCC
Author(s)Matthew T. Campbell, MD, MS, Brian I. Rini, MD
Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
4
Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases
5